Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Vascular Permeability Factor, Etc.); Or Binds Serum Protein, Plasma Protein, Fibrin, Or Enzyme Patents (Class 424/158.1)
  • Patent number: 11459376
    Abstract: The present disclosure provides compositions and methods for treating a disease or condition in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising a plurality of particles comprising at least one therapeutic biologic suspended in a pharmaceutically acceptable liquid carrier.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: October 4, 2022
    Assignee: Elektrofi, Inc.
    Inventors: Paul Brown, Tyler L. Carter, Lyndon Fitzgerald Charles, Jr., Chase Spenser Coffman, Daniel Benjamin Dadon, Lisa Liu, Sadiqua Shadbar, Chaitanya Sudrik, Yi Tang, Shankul Vartak
  • Patent number: 11440969
    Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: September 13, 2022
    Assignee: Genentech, Inc.
    Inventors: Mark Lackner, Daniel Maslyar, Yulei Wang, Walter Darbonne, Eric Humke
  • Patent number: 11433140
    Abstract: Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: September 6, 2022
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Beatrix Stelte-Ludwig, Dennis Kirchhoff, Sandra Berndt, Lisa Dietz, Stephan Märsch, Stefanie Hammer
  • Patent number: 11353458
    Abstract: Methods are provided for determining prognosis of multiple myeloma in a patient by measuring expression of BCMA in a sample. Also provided are methods for treating multiple myeloma by measuring expression of BCMA in a sample and administering an effective amount of an antigen binding protein that binds BCMA. Also provided are kits for measuring BCMA expression in a sample.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: June 7, 2022
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Danton Bounds, Jenny L. Craigen, William E. Fieles, Fiona M. Germaschewski, Gaelle Herledan, Lydia Lee, Patrick A. Mayes, Lee McCahon, Katherine (Nee Sully) Nevin, Jennifer Paterson, Manuel Rodriguez-Justo, Laura M. Seestaller-Wehr, James Tunstead, Kwee L. Yong
  • Patent number: 11332545
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: May 17, 2022
    Assignee: ROCHE GLYCART AG
    Inventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Patent number: 11312766
    Abstract: Provided herein are monoclonal antibodies (e.g., human antibodies) binding to human Growth Differentiation Factor 15 protein (hereinafter, sometimes referred to as “GDF15”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: April 26, 2022
    Assignee: NOVARTIS AG
    Inventors: Hong Chen, Rajiv Chopra, Seung Wan Hahm, Norio Hamamatsu, Ryan Scott Streeper, Mei Xu
  • Patent number: 11299495
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: April 12, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Patent number: 11291709
    Abstract: Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: April 5, 2022
    Assignee: RANI THERAPEUTICS, LLC
    Inventors: Mercedes Morales, Mir Imran, Radhika Korupolu, Mir Hashim
  • Patent number: 11261255
    Abstract: Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: March 1, 2022
    Assignee: Shanghai Henlius Biotech, Inc.
    Inventors: Weidong Jiang, Pei-Hua Lin
  • Patent number: 11249071
    Abstract: Methods of prohibiting Xist-dependent silencing of X chromosome genes include targeting the required Xist silencing complex components including SHARP, SMRT, HDAC3, SAF-A, LBR, and the respective binding sites of SHARP, LBR, and SAF-A on Xist, thereby prohibiting Xist repression, allowing for reactivation of the silenced X chromosome genes.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: February 15, 2022
    Assignee: California Institute of Technology
    Inventors: Mitchell Guttman, Chun-Kan Chen, Colleen A. McHugh
  • Patent number: 11243205
    Abstract: The present invention relates generally to a method of prognosing the survival of a patient with a breast neoplasm, more particularly a patient with a breast neoplasm which is estrogen receptor-/progesterone receptor-/HER-2-(“triple-negative”). The method of the present invention more particularly provides a method for prognosing breast cancer patient survival, in particular risk of metastatic spread, by screening for IRF9 expression. In a related aspect, the present invention provides a method of therapeutically or prophylactically treating patients with a triple-negative breast neoplasm, in particular those patients with triple-negative breast neoplasia which is characterised by a poor survival prognosis, still more particularly a high risk of metastatic spread, by upregulating type I IFN levels.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: February 8, 2022
    Assignee: Peter MacCallum Cancer Institute
    Inventor: Belinda Sheree Parker
  • Patent number: 11236391
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: February 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • Patent number: 11203636
    Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: December 21, 2021
    Assignees: YALE UNIVERSITY, Novo Nordisk A/S
    Inventors: Jeffrey Testani, Veena Rao, Rahul Kakkar, Madhav N. Devalaraja, Chih-Hung Lo
  • Patent number: 11185585
    Abstract: Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: November 30, 2021
    Assignee: The Regents of the University of California
    Inventors: Warren Shawn Carbonell, Manish Kumar Aghi
  • Patent number: 11142766
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: October 12, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, William Querbes, James Butler, Stephanie Williams, Abigail Liebow, Gregory Hinkle, Martin A. Maier, Stuart Milstein, Satyanarayana Kuchimanchi, Muthiah Manoharan
  • Patent number: 11129790
    Abstract: A method is provided for reversibly modifying a protein or peptide on its glutamine residue(s) by performing a reaction, such as a transglutaminase-catalyzed reaction, between the protein or peptide and an amine-containing reagent, whereby the reagent is linked through its amine function to a side chain of the glutamine residue. Subjecting the modified protein to an appropriate stimulus regenerates the protein or peptide in its original form.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: September 28, 2021
    Assignee: Northeastern University
    Inventors: Zhaohui Sunny Zhou, George O'Doherty, Shanshan Liu, Kevin Ryan Moulton, Lincoln Ombelets, Amissi Sadiki
  • Patent number: 11116784
    Abstract: Methods of treating ischemic tissue injury or kidney disease, e.g., delayed graft function, that include administering a Nicotinamide adenine dinucleotide (NAD)/niacinamide (NAM) pathway agonist.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: September 14, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Samir M. Parikh
  • Patent number: 11111288
    Abstract: This disclosure relates to a chimeric antigen receptor for binding with a tumor specific target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region evolved from a parent protein or a fragment thereof and having a decrease in activity in the assay at the normal physiological condition compared to the activity in the assay under the aberrant condition. A method for producing the chimeric antigen receptor is also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: September 7, 2021
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11098117
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: August 24, 2021
    Assignee: Agenus Inc.
    Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
  • Patent number: 11085924
    Abstract: The present invention provides a method for evaluating the risk of occurrence of cancer in an individual.
    Type: Grant
    Filed: January 2, 2017
    Date of Patent: August 10, 2021
    Assignee: Syncerus S.À. R.L.
    Inventor: Jean-Francois Floch
  • Patent number: 11028129
    Abstract: In alternative embodiments, provided are compositions, including e.g., isolated, synthetic or recombinant peptides or polypeptides, for: expanding regulatory T cells (Treg) populations; or, for treating, ameliorating, preventing or reversing a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities and the same or similar types of acute or chronic vascular inflammatory abnormalities, and methods for making and using them.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: June 8, 2021
    Assignee: The Regents of the University of California
    Inventor: Alessandra Franco
  • Patent number: 11027014
    Abstract: The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGF?1, TGF?3, and/or GDF-15.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: June 8, 2021
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Lai-Ming Yung, Paul B. Yu
  • Patent number: 11001640
    Abstract: The present invention provides a method for generating bispecific shark variable antibody domains (vNAR domains) and uses thereof. The present invention further provides fusion proteins comprising the inventive bispecific vNAR domains as well as polynucleotide libraries for use in the generation of the inventive bi-specific vNARs. Furthermore, the invention provides pharmaceutical compositions comprising the inventive bispecific vNARs or fusion proteins comprising bi-specific vNAR domains for use in the treatment of pathological conditions in an individual. The invention also provides kits of parts comprising the bispecific vNAR domains or fusion proteins.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: May 11, 2021
    Assignee: Merck Patent GmbH
    Inventors: Stefan Becker, Bjoern Hock, Stefan Zielonka, Harald Kolmar, Martin Empting
  • Patent number: 10994008
    Abstract: Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: May 4, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gu Danling, Amy M. Beebe
  • Patent number: 10975145
    Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: April 13, 2021
    Assignee: Novartis AG
    Inventors: Tom Thuren, Andrew Zalewski, Michael Shetzline
  • Patent number: 10953105
    Abstract: Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: March 23, 2021
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Darrell Irvine, Haipeng Liu
  • Patent number: 10941210
    Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: March 9, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas Macdonald
  • Patent number: 10912770
    Abstract: The invention relates to the use of adenosine monophosphate deaminase 2 (AMPD2) inhibitors alone or in combination with various agents to treat a wide variety of diseases including, but not limited to, sugar craving, salt craving, umami craving, and addictions including drug, tobacco, nicotine and alcohol addictions. Embodiments of the invention may also relate to stimulation of AMPD2 activity to treat anorexia nervosa or stimulate food intake in a subject.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 9, 2021
    Assignee: Regents of the University of Colorado, A Body Corporate
    Inventors: Richard J Johnson, Ana Andres Hernando, Miguel A Lanaspa Garcia
  • Patent number: 10906951
    Abstract: NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to add mutant (variant) TRAIL ligand expression.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: February 2, 2021
    Assignee: ONK THERAPEUTICS LIMITED
    Inventor: Michael Eamon Peter O'Dwyer
  • Patent number: 10858413
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 8, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Ellen Chi
  • Patent number: 10858420
    Abstract: A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: December 8, 2020
    Assignee: NOVELMED THERAPEUTICS, INC.
    Inventor: Rekha Bansal
  • Patent number: 10829559
    Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: November 10, 2020
    Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
    Inventors: Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
  • Patent number: 10822385
    Abstract: The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: November 3, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Jianhe Chen, Jesper F. Lau, Janos Tibor Kodra, Birgit Wieczorek, Lars Linderoth, Henning Thoegersen, Salka Elboel Rasmussen, Patrick William Garibay
  • Patent number: 10815305
    Abstract: The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: October 27, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jamie M. Orengo, Jeanne Allinne, Andrew J. Murphy, George D. Yancopoulos
  • Patent number: 10793622
    Abstract: The invention provides a three-step chromatography process for small and large-scale purification of proteins, specifically monoclonal antibodies, using only four buffer solutions made from a mother solution.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: October 6, 2020
    Assignee: SANOFI
    Inventors: Didier Duthe, Celine Hemet, Laure Landric-Burtin, Benoit Mothes
  • Patent number: 10783349
    Abstract: Techniques are described for determining the quality of a nerve graft by assessing quantitative structural characteristics of the nerve graft. Aspects of the techniques include obtaining an image identifying laminin-containing tissue in the nerve graft; creating a transformed image using a transformation function of an image processing application on the image; using an analysis function of the image processing application, analyzing the transformed image to identify one or more structures in accordance with one or more recognition criteria; and determining one or more structural characteristics of the nerve graft derived from a measurement of the one or more structures.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: September 22, 2020
    Assignee: AXOGEN CORPORATION
    Inventor: Curt Deister
  • Patent number: 10781252
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 22, 2020
    Assignees: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Patent number: 10745475
    Abstract: The invention relates to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of inflammatory disorders such as rheumatoid arthritis according to specific dosing regimen. The invention relates also to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of pain, e.g. pain experienced in inflammatory disorders such as rheumatoid arthritis, according to specific dosage regimen.
    Type: Grant
    Filed: September 1, 2014
    Date of Patent: August 18, 2020
    Assignee: TAKEDA GMBH
    Inventors: Thomas Wagner, Malin Carlsson, Margit Staum Kaltoft
  • Patent number: 10739352
    Abstract: A method of diagnosis or prediction of infection of a mammalian wound, said method comprising the step of detecting the presence of a cytokine selected from the group comprising procalcitonin, amino procalcitonin (N-ProCT), eotaxin, granulocyte macrophage colony stimulating factor (GM-CSF), interleukins IB monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 alpha (MIP-1a), regulated upon activation normal T expressed and secreted (RANTES) in fluid taken from the wound. Also claimed is the device for use in the method.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: August 11, 2020
    Assignee: CONVATEC TECHNOLOGIES INC.
    Inventors: Philip Godfrey Bowler, Samantha Alison Jones, Sarah Anne Welsby
  • Patent number: 10736900
    Abstract: The invention relates to a combination of a FGFR inhibitor and an IGF1R inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for the treatment of cancer. The FGFR inhibitor and the IGFR inhibitor can be administered simultaneously, separately or sequentially. The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: August 11, 2020
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Eleonora Jovcheva, Timothy Pietro Suren Perera
  • Patent number: 10729769
    Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: August 4, 2020
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Gianluca Rinaldi, Silvia Fratarcangeli, Alessandra Del Rio
  • Patent number: 10696738
    Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: June 30, 2020
    Assignee: Glaxon Group Limited
    Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
  • Patent number: 10683368
    Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein a) the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and b) the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and c) the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprisi
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: June 16, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ekkehard Moessner, Tilman Schlothauer
  • Patent number: 10683349
    Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 16, 2020
    Assignee: NOVARTIS AG
    Inventors: Franco E. Di Padova, Thomas Huber, Jean-Michel Rene Rondeau
  • Patent number: 10656153
    Abstract: Devices, solutions and method capable of quantifying a clinically significant amount of antibodies within a plasma sample obtained from an individual by quantifying binding between antibodies within the sample and microbial proteins are disclosed.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 19, 2020
    Assignee: PZM DIAGNOSTICS, LLC
    Inventor: Peilin Zhang
  • Patent number: 10640558
    Abstract: The present invention provides antibodies that bind to human interleukin-25 (IL-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind human IL-25 and block IL-25-mediated cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies. The antibodies of the invention are useful for the treatment of various disorders associated with IL-25 activity or expression, including asthma, allergy, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, atopic dermatitis (AD), and Eosinophilic Granulomatosis with Polyangiitis (EGPA), also know as Churg-Strauss Syndrome.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: May 5, 2020
    Assignee: REGENERON PHAMACEUTICALS, INC.
    Inventors: Jamie M. Orengo, Jeanne Allinne
  • Patent number: 10570199
    Abstract: The present invention relates to a human anti-human IL-18 antibody which reacts with human interleukin-18 (human IL-18) and does not react with a K53A variant of human IL-18.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: February 25, 2020
    Assignee: KM Biologics Co., Ltd.
    Inventors: Hiroyuki Shimizu, Miyuki Matsumoto, Kenji Soejima, Masaharu Torikai, Toshihiro Nakashima
  • Patent number: 10526402
    Abstract: The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody, e.g. fresolimumab or 1D11.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: January 7, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D'Andrea, Kalindi Parmar, Haojian Zhang
  • Patent number: 10500252
    Abstract: The present invention provides a method of treating an intracellular infection in a subject wherein the method comprising administering to the subject an IAP antagonist. In certain embodiments the IAP antagonist is a Smac mimetic.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: December 10, 2019
    Assignee: WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH
    Inventors: Marc Pellegrini, Gregor Klaus-Peter Ebert, Colin Glenn Begley
  • Patent number: 10478497
    Abstract: The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: November 19, 2019
    Assignee: HYBRIGENICS S.A.
    Inventors: Susan Benjamin, Cécile Planquette, Rémi Delansorne